[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"leiomyoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:leiomyoma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,79,108,133,160],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100650342","terlipressin-vs-placebo-to-reduce-bleeding-in-fibroid-surgery-100650342",false,"NCT07746349","Terlipressin vs Placebo to Reduce Bleeding in Fibroid Surgery","Efficacy of Subcapsular Diluted Terlipressin Versus Placebo in Reducing Intraoperative Blood Loss During Myomectomy: A Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n* Symptomatic uterine fibroid(s) with an indication for myomectomy, including menorrhagia, pelvic pain\u002Fpressure, or infertility\n* Largest myoma diameter between 4 and 10 cm\n* Baseline hemoglobin ≥ 9 g\u002FdL\n* Not pregnant at the time of enrollment\n* Negative urine pregnancy test or last menstrual period within 4 weeks\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* History of bleeding disorders or coagulopathy\n* Current anticoagulant or antiplatelet therapy\n* Known hypersensitivity or contraindication to terlipressin\n* Uncontrolled hypertension\n* Severe cardiac arrhythmia\n* Uncontrolled ischemic heart disease\n* Peripheral vascular disease\n* Pregnancy or suspected pregnancy\n* Previous myomectomy\n* Concurrent pelvic pathology requiring additional surgical intervention\n* Treatment with a GnRH agonist or ulipristal acetate within the 3 months preceding surgery\n* Suspected uterine malignancy, such as leiomyosarcoma\n* Inability to understand or provide informed consent","FEMALE",{"count":18,"type":19},80,"ESTIMATED","INTERVENTIONAL",[22],"NA","A myomectomy is a surgery to remove noncancerous growths (fibroids) from the uterus while keeping the uterus in place. This surgery can cause significant blood loss. Terlipressin is a medicine that narrows blood vessels and may help reduce bleeding.\n\nThis study will test whether injecting a diluted terlipressin solution under the outer covering of the fibroid, before it is removed, reduces the amount of blood lost during surgery, compared to an inactive solution (placebo). Women scheduled for myomectomy will be randomly assigned to receive either terlipressin or placebo. Neither the patients nor the surgical team will know which one was given until the study is finished. The main question this study will answer is how much blood is lost during surgery in each group.",[25,26,27],"Uterine Fibroids (Leiomyoma)","Uterine Myoma","Leiomyoma",[29,30,31,32,33,34,35],"Terlipressin","Myomectomy","Uterine Fibroids","Subcapsular Injection","Intraoperative Blood Loss","Vasopressin Analog","Placebo-Controlled Trial","NOT_YET_RECRUITING","2026-07-31",{"date":39,"type":40},"2026-08-05","ACTUAL",{"date":42,"type":19},"2026-08-01",{"date":44,"type":19},"2027-01",{"name":46,"class":47},"Sevil Cankaya","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":16,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":20,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100527120","phase-4-prescription-of-letrozole-for-uterine-myoma-100527120","NCT06143631","Prescription of Letrozole for Uterine Myoma","Letrozole for Treatment of Uterine Fibroids: A Randomized, Placebo-Controlled Trial","PLUM","Inclusion Criteria:\n\n* At least 21 and less than 54 years of age (to focus on an adult, premenopausal population)\n* Female sex, based on sex identified on their birth certificate (no other gender requirements)\n* Have uterine leiomyomata that have been visualized on pelvic imaging (i.e., ultrasound or MRI) in the last 24 months\n* Report symptoms associated with leiomyomata such as heavy uterine bleeding, pelvic pressure or discomfort, urinary or bowel abnormalities, or dyspareunia for the past 3 months\n* Have at least moderate leiomyomata symptom burden, with UFS-QOL SSS score of 30 or higher at baseline\n* Has had a menstrual period in the past 3 months (90 days)\n* Agree to use a non-hormonal or barrier method of contraception with any sexual activity with a non-sterile male partner during the study period (i.e., use of copper IUD is consistent with eligibility)\n\nExclusion Criteria:\n\n* Screening pelvic imaging indicating any leiomyomata ≥10 cm in maximum diameter, or uterine size ≥16 cm in length (equivalent to 16 weeks gestation)-note that candidates who exclusively have prior clinical pelvic imaging 12-24 months ago will be excluded if imaging includes leiomyomata ≥9 cm in maximum diameter, or uterine size ≥15 cm in length, presuming leiomyoma growth of ≥1 cm per year\n* Screening pelvic imaging indicating only one, sole leiomyoma \\\u003C2 cm in maximum diameter\n* Any submucosal leiomyoma that is \\>50% within uterine cavity (FIGO Type 0 or Type 1 leiomyomata)\n* Visit to the emergency room or hospitalization for leiomyoma symptoms in the last 12 weeks\n* Leiomyomata treated by surgery, radiologic procedure in the last 12 weeks; or plans to undergo any of the above in the next 24 weeks\n* Leiomyomata treated by GRNH agonist or antagonist in the last 12 weeks (if injected) or in the last 4 weeks (if oral); or plans to use the above in the next 24 weeks\n* Currently pregnant or lactating, pregnant or lactating in the past 12 weeks, or planning to become pregnant in the next 24 weeks\n* Screening serum hemoglobin \\\u003C8 g\u002FdL, or history of blood transfusion in the last 12 weeks (indicating severe anemia)\n* Screening cholesterol lipid panel testing showing LDL cholesterol level ≥ 190 mg\u002FdL (due to rare side effects over long-term use of aromatase inhibitors in postmenopausal women)\n* Screening serum estradiol level \\\u003C30 pg\u002FmL (consistent with postmenopausal status)\n* For women aged 45 years or older only: irregular menstrual cycles (menstrual cycles \\\u003C21 days or \\>38 days between periods), prolonged menstrual bleeding (bleeding \\>14 days), or bleeding in between menstrual periods, unless already evaluated by a clinician to discuss endometrial biopsy (uterine biopsy) to rule out endometrial hyperplasia.\n* History of osteoporosis (based on self-reported DEXA indicating bone mineral density Z-score \\\u003C -2.0 at spine, total hip, or femoral neck; a prior fracture judged to be a fragility fracture; or self-reported use of bisphosphonates, calcitonin, calcitriol, ipriflavone, teriparatide, or denosumab for bone density loss)\n* History of severe liver disease (Child Pugh Class C cirrhosis), posing safety risks for use of letrozole\n* Current or prior history of breast cancer (given potential need to take letrozole for breast cancer treatment or secondary prevention)\n* Screening pelvic imaging indicating an Ovarian-Adnexal Reporting and Data System (O-RADS) category 3, 4, or 5 ovarian or adnexal lesion\n* Screening pelvic imaging concerning for other current cancer of the gynecologic, genitourinary or gastrointestinal system\n* Prior hypersensitivity or significant adverse reaction to letrozole or any aromatase inhibitor, or to an ingredient in the placebo capsule\n* Use of letrozole, other aromatase inhibitor, or selective estrogen receptor modulator (SERM) medications in the past 4 weeks, or existing plans to initiate one of these in the next 24 weeks\n* Use of oral, vaginal, or topical exogenous estrogen, progestin, or androgen therapy in the past 4 weeks; or injectable forms of the above in the past 12 weeks; or plans to initiate any of the above in the next 24 weeks\n* Use of medications with potential unsafe interactions with letrozole in the past 4 weeks (methadone, levomethadone, nintedanib, thalidomide), or plans to initiate these in the next 24 weeks\n* Any condition that, in the opinion of the investigators, would interfere with ability to complete study procedures, including acute or uncontrolled mental health condition, substance abuse, or inability to complete procedures in English (or Spanish, for sites that offer study assessments in Spanish)",true,"21 Years","53 Years",{"count":60,"type":19},140,[62],"PHASE4","The PLUM Study is a randomized, double-blinded, 2-arm, parallel-group, placebo-controlled trial is designed to compare the efficacy of letrozole versus placebo on leiomyoma-related symptoms and quality of life as well as leiomyoma and uterine size.",[65,27,66,67],"Leiomyoma, Uterine","Fibroid","Fibroid Uterus","RECRUITING","2026-07-20",{"date":71,"type":40},"2026-07-22",{"date":73,"type":40},"2024-07-24",{"date":75,"type":19},"2028-12-11",{"name":77,"class":47},"University of California, San Francisco",5,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":92,"conditions":93,"keywords":94,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100526525","role-of-senescent-cells-in-uterine-fibroid-pathogenesis-soul-study-100526525","NCT06135870","Role of Senescent Cells in Uterine Fibroid Pathogenesis (SOUL Study)","Role of Senescent Cells in Uterine Fibroid Pathogenesis","SOUL","Inclusion Criteria:\n\n* Subjects must be women above the age of ≥18 - ≤55 years.\n* Women with suspected uterine fibroids.\n* Subject must be or have been sexually active or have had a previous vaginal exam that used a speculum.\n* Subject must be able to understand, read and speak English or Spanish and subsequently, be able to understand what she is consenting to in terms of procedures and use\u002Fdisclosure of protected health information.\n\nExclusion Criteria:\n\n* Unwilling to sign the consent form or complete questionnaire.\n* Pregnancy.\n* Cancer of the uterus","18 Years","55 Years",{"count":90,"type":19},150,"OBSERVATIONAL","The investigators are evaluating the role of senescent cells in uterine fibroids.",[66,27],[95,96,97],"Senescent cells","Fibroids","Leiomyomas","2025-12-05",{"date":100,"type":40},"2025-12-11",{"date":102,"type":40},"2023-11-01",{"date":104,"type":19},"2027-12-31",{"name":106,"class":47},"Johns Hopkins University",1,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":20,"phases":119,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":107},"100598991","an-open-label-study-to-evaluate-the-effect-of-elix-cycle-balance--elix-daily-harmony-on-fibroid-related-symptoms-100598991","NCT07078682","An Open-Label Study to Evaluate the Effect of Elix Cycle Balance & Elix Daily Harmony on Fibroid-related Symptoms","An Open-Label, Single-Group Study to Evaluate the Effect of Elix Cycle Balance & Elix Daily Harmony on Fibroid-related Symptoms","Inclusion Criteria:\n\n* Be female.\n* Be aged 20-45.\n* BMI 18.5 - 24.9 kg\u002Fm2\n* Self-reported prior diagnosis of uterine fibroids.\n* Anyone who is generally healthy - does not live with any uncontrolled chronic disease.\n* Self-reported moderate to severe discomfort during menstruation, related to pelvic cramps, bloating, mood swings, or fatigue.\n* Self-reported menstrual cramps during their cycle, for the past six months minimum.\n* If taking hormonal birth control, has been doing so consistently for at least three months, and experiences a menstrual cycle with a period.\n* If taking other oral over-the-counter supplements or herbal remedies, has been consistently taking these for at least three months prior to starting the study, and is willing to maintain this routine for the study duration.\n* Willing to refrain from introducing any products or any new forms of medication or supplements for the study duration.\n* Willing to refrain from any other dietary supplements or herbal remedies targeting the menstrual cycle during the study period.\n* Willing to refrain from any new vaccines during the 6 month period.\n* Follows a stable, consistent exercise regimen and are willing, for the duration of the study, to not decrease or increase the amount of exercise in their regimen.\n* Agrees to refrain from any lifestyle changes that may affect their menstrual cycle for the duration of the study (for example, getting on or off hormonal birth control, reducing the amount of exercise).\n* If using any other interventions, such as massage, chiropractic medicine, or acupuncture, agrees not to increase or decrease the number of these other interventions during the study period.\n* Resides in the United States.\n\nExclusion Criteria:\n\n* Does not experience a regular menstrual cycle (21-35 days).\n* Does not experience menstrual cramping.\n* Follows an extreme diet intervention such as dry fasts, water fasts, or ketogenic diets.\n* Anyone who has experienced significant weight loss in the past three months prior to study participation.\n* Unwilling to stop the use of any medication or herbal remedies\u002Fsupplements that can affect the menstrual cycle.\n* Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.\n* Anyone with known severe allergic reactions.\n* Anyone with any allergies or sensitivities to any of the study product ingredients.\n* Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period).\n* Anyone unwilling to follow the study protocol.\n* Has stopped, started, or changed hormonal birth control in the past three months.\n* Previous users of Elix Cycle Balance.\n* Anyone who is currently a smoker or has been a smoker in the past 3 months.\n* Anyone who has been diagnosed with the following conditions: PCOS, Endometriosis, PMDD, Adenomyosis, Hashimoto's thyroiditis, Grave's disease (and any other thyroid disorders), hyperprolactinemia, Cushing's disease, congenital adrenal hyperplasia, anorexia, bulimia, orthorexia, binge eating, any other eating disorder.\n* History of endocrine disorders such as thyroid disorder, Type 1 or 2 diabetes, or other.\n* History of hypertension, hyperlipidemia, or previous venous embolism.\n* Overweight\u002Fobesity (BMI \\> 25 kg\u002Fm2).\n* Women with other causes of chronic pelvic pain, including infectious disease, gastrointestinal, psychological disorders, fibromyalgia, and chronic fatigue syndrome.\n* Hysterectomy, myomectomy, or bilateral salpingo-oophorectomy or other gynecological medical or surgical treatment in the last 6 months.\n* History of an abnormal pap smear.\n* History of neoplasia of gynecological origin and\u002For existence of uterine malformations.\n* Chronic urinary tract infections or diagnosed functional gastrointestinal conditions like IBS, IBD, Crohn's disease, or ulcerative colitis.\n* Currently partaking in another research study or will be partaking in any other research study for the next 24 weeks, or at any point during this study's duration.\n* Consume more than 5 alcoholic drinks per week\n* Had a vaccine in the last 3 months","20 Years","45 Years",{"count":118,"type":19},42,[22],"This is a 24-week, single-arm, open-label, virtual study evaluating the effects of Elix Cycle Balance and Elix Daily Harmony on uterine fibroid-related symptoms and quality of life in 42 participants. Participants will self-administer the investigational herbal supplements daily and complete validated questionnaires at scheduled timepoints to assess symptom severity and quality of life.",[31,27,122],"Menstrual Pain","2025-09-07",{"date":125,"type":40},"2025-09-12",{"date":127,"type":40},"2025-08-01",{"date":129,"type":19},"2026-01",{"name":131,"class":132},"Zenchi, Inc.","INDUSTRY",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":140,"minAge":87,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":144,"conditions":145,"keywords":148,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":107},"100601124","ceh-eus-for-differentiating-gists-and-leiomyomas-a-multicenter-prospective-self-controlled-study-100601124","NCT07106411","CEH-EUS for Differentiating GISTs and Leiomyomas: A Multicenter Prospective Self-Controlled Study","Contrast-Enhanced Harmonic Endoscopic Ultrasound for the Differential Diagnosis Between Gastrointestinal Stromal Tumors and Leiomyomas: A Multicenter Prospective Self-Controlled Study","Inclusion Criteria:\n\n* Age ≥18 years and ≤ 85 years;\n* Subepithelial lesion in the gastrointestinal tract identified under white-light endoscopy and scheduled for CEH-EUS examination to determine the nature of the lesion;\n* EUS image quality meets the following quality control standards:\n\n  1. Equipment requirements: EU-ME2 processor (Olympus, Tokyo, Japan) and GF-UCT260 \u002F GF-UE260 echoendoscope (Olympus, Tokyo, Japan);\n  2. Image acquisition: Five EUS still images clearly displaying the lesion and surrounding structures, including maximum lesion diameter, originating layer, Doppler signals, and internal echo characteristics; a 15-second video clearly demonstrating the lesion without any artificial annotations (e.g., scale, needle, Doppler signal, elastography, etc.);\n  3. CEH-EUS procedure: Use of extended pure harmonic detection (Ex-PHD) mode with mechanical index (MI) adjusted to 0.3; 2.4 mL of SonoVue contrast agent is injected via the elbow vein within 2-3 seconds, followed by a 5 mL saline flush; real-time dynamic image acquisition continues for 120 seconds, and video recording is collected.\n* Patients with GIST confirmed by surgical or endoscopic resection pathology, and patients with leiomyoma confirmed by surgical resection, EUS-guided tissue sampling, or other biopsy techniques;\n* Written informed consent is obtained.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years or \\>85 years;\n* Hemoglobin level ≤8.0 g\u002FdL;\n* Known allergy or hypersensitivity to ultrasound contrast agents;\n* Pregnant women;\n* Severe cardiopulmonary dysfunction that precludes tolerance of endoscopic ultrasound examination;\n* Inability to provide written informed consent (e.g., due to psychiatric disorders or substance abuse).","ALL","85 Years",{"count":143,"type":19},288,"The investigators conduct a prospective, multicenter diagnostic trial primarily aimed at evaluating the value of contrast-enhanced harmonic endoscopic ultrasound (CEH-EUS) in differentiating gastrointestinal stromal tumors (GISTs) from leiomyomas, as well as its predictive utility in the risk stratification of GISTs.",[146,147,27],"Submucosal Tumor","Gastrointestinal Stromal Tumor (GIST)",[149,150],"Endoscopic ultrasound","Contrast-Enhanced Ultrasonography","2025-07-30",{"date":153,"type":40},"2025-08-06",{"date":155,"type":19},"2025-08",{"date":157,"type":19},"2026-10",{"name":159,"class":47},"Huazhong University of Science and Technology",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":140,"minAge":87,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":169,"conditions":170,"keywords":172,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":179,"leadSponsor":181,"locationsCount":107},"100598949","multicenter-observational-study-of-multimodal-ai-for-upper-gi-mesenchymal-tumor-diagnosis-100598949","NCT07078136","Multicenter Observational Study of Multimodal AI for Upper GI Mesenchymal Tumor Diagnosis","Multicenter Observational Study of a Multimodal AI Model Using EUS, White-Light Endoscopy, and Clinical Data for Diagnosis of Upper GI Mesenchymal Tumors and Risk Stratification of Gastric GISTs","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Patients with an upper gastrointestinal subepithelial lesion (SEL) identified by white-light endoscopy and who have completed an endoscopic ultrasound (EUS) examination\n* Patients with a histopathological diagnosis of GIST confirmed by surgical or endoscopic resection, or other SELs confirmed by surgical resection, EUS-guided sampling, or other biopsy techniques\n* EUS image quality meets the following quality control standards\n\n  1. Equipment requirements: Olympus EU-ME2\u002FME1 processor (Olympus Medical Systems Corp., Tokyo, Japan); radial EUS scope (GF-UE260\u002FGF-UE240; Olympus, Tokyo, Japan) or linear EUS scope (GF-UCT260\u002FGF-UCT240; Olympus, Tokyo, Japan); miniature probe (UM2R\u002F3R; Olympus, Tokyo, Japan); Pentax ARIETTA 850 processor (Pentax, Tokyo, Japan); radial EUS scope (EG-3670URK, Pentax, Tokyo, Japan); linear EUS scope (EG-3870UT, Pentax, Tokyo, Japan); Fujifilm SU-8000 or SU-9000 processor; linear EUS scope (EG-580UT, Fujifilm, Tokyo, Japan); radial EUS scope (EG-580UR, Fujifilm, Tokyo, Japan)\n  2. EUS images clearly showing the lesion and surrounding tissue characteristics (at least 5 images or video); must include at least one image of the maximum lesion diameter, one image showing the layer of origin, and one image demonstrating the growth pattern (intraluminal\u002Fextraluminal)\n  3. EUS images must not contain artificial annotations, such as measurement scales, biopsy needles, Doppler signals, or elastography overlays\n  4. Image resolution must be at least 448 × 448 pixels\n* WLE (white-light endoscopy) image quality meets the following standards: images must clearly show the lesion location, mucosal features, and margins; at least one close-up and one distant view\n* Complete clinical data and histopathological reports must be available\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years old\n* Absolute contraindications for EUS examination, history of gastric surgery, pregnancy, severe comorbidities, or known allergy to anesthetic agents\n* EUS examination terminated prematurely due to esophageal stricture, obstruction, large space-occupying lesions, rapid changes in heart rate or respiratory rate, patient intolerance, or excessive residual food\n* EUS image quality does not meet the required quality control standards\n* Pathological specimens do not meet diagnostic requirements: insufficient biopsy tissue (only R0 resection specimens are accepted for the GIST group), or incomplete immunohistochemical staining (missing CD117\u002FCD34\u002FDOG-1 expression report for the GIST group)\n* Pathological results indicate that the lesion is a metastatic tumor originating from another site",{"count":168,"type":19},130,"This study develops a multimodal AI model using endoscopic ultrasound, white-light endoscopy, and clinical information to support the diagnosis of upper GI mesenchymal tumors and the risk stratification of gastric GISTs.",[146,147,27,171],"Schwannoma",[173,149,174],"Artificial Intelligence","white-light endoscopy","2025-07-28",{"date":177,"type":40},"2025-07-31",{"date":175,"type":40},{"date":180,"type":19},"2026-06",{"name":159,"class":47}]